Latest News for: vegf

Edit

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific ...

Nasdaq Globe Newswire 05 Jan 2026
CR-001 IND cleared by U.S.
Edit

Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"

PR Newswire 10 Nov 2025
Tosposertib (TU2218) is a highly potent, oral dual inhibitor designed to block the signaling pathways of transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), two critical mediators of tumor growth and metastasis.
Edit

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at ...

Nasdaq Globe Newswire 04 Nov 2025
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity. IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors ... .
Edit

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at ...

Nasdaq Globe Newswire 04 Nov 2025
BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc ... .
  • 1

Article Search

tools
×
×
×
×